Rural Expansion of Medication Treatment for Opioid Use Disorder: Randomized Controlled Pilot Trial of Extended-release Buprenorphine vs. Sublingual Buprenorphine-naloxone in Rural Settings (NIH HEAL Initiative)

Funded by the NIH HEAL Initiative®

This randomized, open-label pilot study will assess the feasibility, acceptability, and effectiveness of extended-release buprenorphine (XR-BUP, CAM2038), compared with sublingual buprenorphine-naloxone (SL-BUP) for treatment of opioid use disorder (OUD) among rural patients.  Relative effectiveness of XR-BUP vs SL-BUP in rural populations with OUD has not been subjected to research, and this project seeks to rapidly develop new knowledge on the issues to support future large-scale trials. Findings will suggest possible next steps for additional research and will inform scaling of the implementation to improve capacity to utilize extended-release MOUD and increase MOUD access and uptake of extended-release MOUD in rural communities. 

CTN Protocol ID: 
CTN-0102-XR
Status: 
Development

Principal Investigator(s)

Yih-Ing Hser, Ph.D.

Integrated Substance Abuse Programs
University of California

11075 Santa Monica Boulevard
Suite 200
Los Angeles, CA 90025
United States

Larissa Mooney, M.D.

Associate Clinical Professor
University of California, Los Angeles
Department of Psychiatry and Biobehavioral Sciences Integrated Substance Abuse Programs

11075 Santa Monica Boulevard, Suite 200
Los Angeles, CA 90025
United States